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Abstract Observational studies have been recognised to
be essential for investigating the safety profile of medica-
tions. Numerous observational studies have been con-
ducted on the platform of large population databases,
which provide adequate sample size and follow-up length
to detect infrequent and/or delayed clinical outcomes.
Cohort and case–control are well-accepted traditional
methodologies for hypothesis testing, while within-indi-
vidual study designs are developing and evolving,
addressing previous known methodological limitations to
reduce confounding and bias. Respective examples of
observational studies of different study designs using
medical databases are shown. Methodology characteristics,
study assumptions, strengths and weaknesses of each
method are discussed in this review.
Keywords Methodology  Observational study 
Pharmacoepidemiology
Impacts on practice
• The advancement of observational study design allows
pharmacists and researchers to gain better understand-
ing of the incidences and causes of adverse drug events.
This can enhance the patient safety and ultimately
better care for patients.
Introduction
The importance of observational studies in the evaluation of
drug safety has been recognised in recent decades, along
with the ongoing interest about drug adverse events over
time. Data generated from observational studies supplement
premarketing experimental trials, especially in situations
where the outcome of drug exposure is rare, delayed or
observed in specific subgroups. In such cases, large data-
bases offer a platform with relatively large sample size, long
follow-up period and few ethical issues, which are cost-
effective and efficient compared to interventional studies.
Since the 1980’s, substantial observational studies have
been conducted using large databases. Databases used should
ideally include a large and stable population, be representa-
tive and verifiable. Based on the source and type of data,
databases are generally divided into two types, administrative
databases and clinical databases. Administrative databases,
include the Medicaid (United States [US]) and the National
Health Insurance Research Database (NHIRD, Taiwan),
which functions primarily as insurance claims databases [1,
2]. Clinical databases, on the other hand contain electronic
medical records entered for clinical use and patient moni-
toring. Such databases include the Clinical Data Analysis and
Reporting System database (CDARS, Hong Kong) and the
Clinical Practice ResearchDatalink (CPRD, UnitedKingdom
[UK]) [1, 2]. With both types of database, observational
studies can be conducted using different study designs.
Considered as fundamental or traditional methods,
cohort and case–control design are widely applied but can
be vulnerable to confounder and selection bias. To tackle
& Ian C. K. Wong
I.wong@ucl.ac.uk
1 Department of Pharmacology and Pharmacy, Centre for Safe
Medication Practice and Research, Li Ka Shing Faculty of
Medicine, The University of Hong Kong, 2/F Laboratory
Block, 21 Sassoon Road, Pok Fu Lam, Hong Kong SAR,
China
2 School of Pharmacy, University College London, 29-39
Brunswick Square, London WC1N 1AX, UK
123
Int J Clin Pharm (2016) 38:676–684
DOI 10.1007/s11096-016-0285-6
methodological limitations, new study designs for obser-
vational studies have been developed to eliminate or at least
minimise the effect of time-invariable factors. Within-in-
dividual designs, including self-controlled case series study
(SCCS) [3] and case-crossover study (CCO) [4], introduced
since the early 1990’s, are now widely used for observation
and evaluation of drug safety and effectiveness.
The aim of this review is to introduce readers to the
design of conventional and innovational observational
methods for drug safety and effectiveness research. This
review will present the characteristics, assumptions,
strengths and limitations of each method. Examples of each
method are also given to illustrate their application.
Cohort study
Characteristics
A cohort study is used to examine causal factors [5]. This
type of study recruits a group of subjects to represent the
population of interest. Subjects are included at commence-
ment of the study and classified as exposed (treatment
group) or non-exposed (control group), based on their drug
exposure status (Fig. 1). In some cohort studies, the control
group could have other treatment(s) [6] or a different dose of
the same treatment [7]. Subjects are then followed up over
time to identify the incidence of outcome of interest, usually
adverse events in the treatment and control groups.
Cohort studies can either be prospective or retrospective.
Prospective cohort studies are carried out from present time
to future. It usually starts with the collection of specific
exposure data, but there may be a long wait for events to
occur, particularly where the outcome of interest is a chronic
event. Studies can therefore be expensive to carry out and are
prone to high dropout rates. Conversely, retrospective
cohort studies look at outcome of interest from a time-point
in the past up to the intended study period. The advantage of
retrospective cohort studies is that the information is avail-
able immediately. However, there may be difficulty in
tracing subjects and further information required relies
solely on the already recorded data for such studies. Fur-
thermore, the validity of the database should be carefully
considered, as most databases applied currently may not
have been established for research purposes.
Strength and weakness
Advantages of cohort studies include the fact that exposure
status is determined before the outcome of interest, which
is less likely to be prone to bias. Further, multiple outcomes
can be explored at a time. Also, due to the nature of
recruitment, cohort studies are suitable for studying rare
exposures. On the other hand, prospective cohorts usually
take a long time and are therefore costly. A very large
sample size is also required for rare outcomes.
Example
The use of dabigatran, an inhibitor of thrombin, increases
risk of gastrointestinal bleeding (GIB). However, it is not
clear whether gastroprotective agents (GPAs) prevent GIB
in dabigatran users [8]. Using a retrospective cohort study
design, Chan et al. [8] investigated the association between
the use of GPAs and the risk of GIB in dabigatran users.
Utilising electronic medical records from CDARS, Chan
et al. identified a group of dabigatran users (the cohort)
between 2010 and 2013. Among the cohort, patients who
had a prescription of either histamine type-2 receptor
antagonists and/or proton pump inhibitors during follow-up
were defined as exposed to GPAs whilst others were
defined as unexposed (control). Included patients were then
followed up until the end of the observation period to
ascertain whether they had a diagnosis of GIB (outcome).
Retrospective cohort studies require accurate records for
the exposures and outcomes, Chan et al. used dispensed
medications as exposures and verified diagnosis records as
outcomes to enhance validity as misclassification of
exposures and/or outcomes will bias the results.
To compare the risk of GIB between GPA users and
non-users, Poisson regression was used to determine the
incidence rate ratio (IRR) with 95 % confidence intervals
(CI), among patients who were taking dabigatran. Adjust-
ment in the regression model was made to control for
baseline medical conditions and use of concurrent medi-
cations. The study showed that a reduction of 48 % in the
risk of GIB was found in GPA users as compared with
nonusers (IRR 0.52; 95 % CI 0.35–0.77).
Case–control study
Characteristics
As in cohort studies, the purpose of case–control studies is
to evaluate the association between risk factors and out-
come of interest [5]. In contrast to cohort studies, however,
individuals in the population with the outcome of interest
are identified at the onset (Fig. 1). Risk factors or exposure
information is collected retrospectively. Individuals with
the outcome are determined as cases. Individuals who do
not have the outcome of interest, the controls, are also
included in the study. The case–control study design is
often used in the study of rare outcomes or as a preliminary
study where little is known about the association between
the risk factor and disease of interest.
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Case definition should be precise to distinguish between
stages, severity or subtypes of disease and to define a
measure of health status so that cases and controls for the
study can be chosen appropriately [9]. Controls should
come from the same population at risk of disease, should
not have the disease and should be representative of the
target population. The selection of suitable controls requires
great care in the prevention of bias. Cases and controls can
be matched to address confounding factors which might
contribute to the development of disease and confound the
causal association under investigation. A case–control study
conducted in a specified cohort is called a nested case–
control study [10]. For many research questions, the nested
case–control design offers a cost effective option and
reduce the time required for data collection and analysis
compared with the full cohort approach, with relatively
minor loss in statistical efficiency.
Strength and weakness
Case–control studies are relatively quick to run and incur
lower costs compared to cohort studies. Case–control
studies are particularly suited to the study of rare diseases
as the diseased are selected at the outset of the study. The
disadvantages, however, include difficulties in selecting
proper cases and controls. Also, it is not possible, to cal-
culate the incidence of the disease in case–control studies.
However, incidence can be estimated in the nested case–
control study.
Example
Combined oral contraceptives are effective in preventing
pregnancy in general. They have, however, measurable
side effects such as venous thromboembolism (VTE),
Fig. 1 Cohort and case control
study designs. In a cohort study,
subjects are classified as an
exposed or non-exposed group
based on their drug exposure
status at study commencement.
Subjects are then followed up
over time to identify any
occurrence of the outcome of
interest. In a case–control study,
subjects are classified as case
and control (non-case) at study
commencement. Subjects with
the outcome of interest are
defined as cases, while subjects
without the outcome of interest
are defined as controls.
Information is collected
retrospectively to identify any
previous drug exposure
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which is a potentially fatal but avoidable prolonged event
[11]. A study by Vinogradova et al. [11] investigated the
association between the use of combined oral contracep-
tives and risk of VTE with two clinical databases (CPRD
and QResearch) in UK. Study population includes all
women without records of VTE before the study, aged
15–49 years, who were registered with the study practices
between 2001 and 2013. For both databases, they matched
each case with up to five controls by birth year and from
the same general practice. Each control was allocated an
index date, which was the date of first VTE diagnosis for
the matched case. Exposure to hormonal contraceptive
drugs was based on prescription information in the last year
before the index date.
To prevent heterogeneity between databases, two nested
case–control studies within each dataset and separate
analyses were conducted. Conditional logistic regression
model was applied to obtain odds ratios (ORs) with 95 %
CI. In addition, imputation model was applied in handling
missing data for body mass index, smoking status, and
alcohol consumption [11]. In total, they identified 7334
incident VTE cases from CPRD and 8211 cases from
QResearch within the study period. Crude incidence of
VTE cases per 10,000 women years was 5.9 in CPRD and
6.1 in QResearch. For the analyses combining results from
both databases, current use of any combined oral contra-
ceptive was associated with a significantly increased VTE
risk (adjusted OR 2.97, 95 % CI 2.78–3.17) compared with
no exposure in the last year.
Cohort and case–control designs are fundamental
methods in observational pharmacoepidemiological
research and have been widely applied. However, as dis-
cussed above, validity of the results can be affected by
biases and confounding effects [12].
Within-individual design
To reduce confounding by using each case as their own
control and eliminate between-individual confounding by
time-invariant factors, within-individual designs are pro-
posed. Such time-invariant factors include socioeconomic
status, family and personal medical history and genetic
factors, which would otherwise be difficult to adjust for
using statistical methods.
A within-individual design, also called case-only or self-
controlled design, is a modified version of the traditional
epidemiological methodologies where there is comparison
between different observation periods within the same
person to estimate an odd ratio or rate ratio [13–15]. Two
main types of within-individual designs are commonly
used in epidemiological research: the self-controlled case
series and case-crossover study. Both designs compare
observation periods within the same individual thus only
subjects with the outcome of interest are identified.
Self-controlled case series (SCCS)
Characteristics
The SCCS was first described by Farrington [3] in the
application of vaccine-associated mumps meningitis. It was
developed to investigate the association between adverse
reactions subsequent to vaccination and is now a com-
monly used study design in pharmacoepidemiological
studies [15–18]. Using this method, a relative incidence is
derived by comparing the rate of events during the exposed
period with the rate during non-exposed periods (Fig. 2).
The exposed period is regarded as fixed, whilst the
occurrence of events is random [14].
Assumptions
Three assumptions should not be violated when applying
SCCS design [19]. First, events should be rare or inde-
pendent of each other. For non-recurrent events (such as
incident events), the risk over the study period should be
small and recurrent events should be independent of each
other since we assume the events occur at random in this
study design.
Secondly, the occurrence of the event should be inde-
pendent of the exposures. The occurrence of the event will
affect the probability of subsequent exposure and bias the
estimate when this assumption is violated, for example, the
event is an indication or contraindication of the exposure.
Lastly, the occurrence of the event or any subsequent
conditions stemming from the event should not censor the
observation period. A typical example of an event that will
censor the observation period is death.
Extension
Several extensions of the SCCS were developed in the past
decade to account for the bias induced when the event
censors the subsequent observation period [20–22], and can
be applied with specific conditions.
Strength and weakness
The major strength of SCCS is that time-invariant con-
founding factors (both measured and unmeasured) are
inherently controlled in the model because within person
comparisons are made. Temporal variables such as age and
progression of disease can also be accounted by subdi-
viding the observation period of each subject into calendar
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years or age categories. In addition, SCCS is less data-
intensive compared to classical cohort and case–control
study designs since only cases are sampled.
Application to certain outcomes of interest or exposure
could be limited by assumptions. However, modified ver-
sions of the design were developed to minimise bias. This
design is also limited to single outcomes of interest. It also
does not provide estimates of absolute incidence but only
relative incidence.
Examples
Several studies are selected to be discussed in detail on
how this design was applied and what was done to abide to
the assumptions of SCCS. Chui et al. [15] investigated the
association between the use of oral fluoroquinolones and
the development of retinal detachment using two databases
from Hong Kong and Taiwan (CDARS and NHIRD). In
this study, the outcome of interest was retinal detachment,
where the first event will affect the subsequent re-occur-
rence of events. In such cases, the incident event of each
subject was considered only in the analysis so that the
assumption that events should be independent of each other
was not violated.
As mentioned previously, the occurrence of the event
should not affect the probability of exposure. Douglas et al.
[17] conducted a SCCS to investigate the use of orlistat and
acute liver injury. They removed the period prior to orlistat
exposure from the non-exposed period to assess whether
orlistat is temporarily affected by the event. Douglas et al.
demonstrated an increased risk of acute liver injury in both
pre-exposure and during exposure of orlistat which sug-
gested a non-causal relationship.
Brauer et al. [16] investigated the use of antipsychotics
and the risk of myocardial infarction (MI). Since MI may
increase the short-term risk of death, the use of SCCS may
result in bias. Therefore, they applied the extended SCCS
method, which removes this assumption by re-parameter-
ising the SCCS model. They found a significant association
between antipsychotics and the risk of MI with an addi-
tional validation of a case–control study.
SCCS is also applicable for evaluating the effectiveness
of medication in practice. Man et al. [23] used SCCS to
evaluate the effectiveness of methylphenidate in the
reduction of Accident and Emergency (A&E) admission in
children with attention deficient hyperactivity disorder due
to trauma. 10 % reduction of A&E admission due to
trauma during treatment period was shown in this study.
Case-crossover design (CCO)
Characteristics
The CCO, another within-individual design, was developed
by Maclure [4] to investigate the risk of acute events. For
each case, the time just before an outcome event is defined
as case-period, and the preceding times are defined as
control-periods (Fig. 3). The exposure status during case-
period is compared to that in the control-periods, typically
using ORs.
Assumptions
The CCO design is one of the most efficient study designs
for investigating the association of transient exposures with
acute outcomes [4, 24]. Although CCO and SCCS depend
on within-individual comparison, the requirement for
event-independent observation period censoring in SCCS
does not apply to the CCO design because the observation
period after the event occurrence is not considered in the
analysis. The CCO design also assumes the exposure has a
Fig. 2 Self-controlled case series study design. Only cases are
included in a self-controlled case series study. For each case, within a
pre-defined observation period, the time period exposed to the drug is
defined as exposed period, while the time period not exposed to the
drug is defined as non-exposed period. The rate of the outcome event
during the exposed periods is compared with that during the non-
exposed periods
680 Int J Clin Pharm (2016) 38:676–684
123
stable trend over time. Indeed, several methods have been
developed to address the bias of CCO when exposure-time
trend exists [25, 26].
Extension
Case–time–control design (CTC)
The CTC design [25] combines CCO with the case–control
design. CTC assumes the ORs obtained from the CCO
analysis is the combined effects of time-trend and exposure
[13]. To obtain the effect of exposure, results will be
adjusted for bias from the effect of time-trend, which is
estimated using concurrent at-risk time exposure status of
non-cases (Fig. 3). In this way, CTC does not require a
stable exposure-time trend.
Case–case–time–control (CCTC)
The CCTC design [13] is an extension of CTC where con-
trols are sampled from future cases instead of non-cases
(Fig. 3). CCTC is suggested to be less prone to protopathic
bias [27], which occurs when early symptoms of an outcome
leads to exposure. Indeed, it has been demonstrated that
future cases can provide a better estimate of the exposure-
time trend among the cases compared to non-cases [13].
Strength and weakness
A major advantage of CCO is that it eliminates con-
founding effects fixed over time within the individual.
However, CCO is subject to bias from confounders that
vary with time [25, 26]. Although CTC and CCTC
accounts for this potential bias, they may reintroduce
control-selection bias if the external controls are not well-
matched [28]. Therefore, depending on the magnitude of
exposure-time trends and the suitability of the matched-
control group, the performance of CCO, CTC, and CTCC
could vary in different scenarios.
Example
Unlike SCCS, the use of CCO design is not prone to the
assumption of event-dependent censoring of observation
period. Using CCO as an internal validation of the SCCS
analysis, Wong et al. [29] studied the association between
the use of Helicobacter pylori eradication treatment con-
taining clarithromycin and cardiovascular outcomes. The
exposure statuses of clarithromycin were compared during
the case and control periods with time windows of 14 days.
Each case acts as self-control and thus implicitly controls
for time-invariant confounders such as the severity of
underlying diseases. The OR estimated was 2.20 (95 % CI
Fig. 3 Case-crossover, case–time–control, and case–case–time–con-
trol study designs. In a case-crossover study, each case acts as a self-
control from previous experience. Case period is defined as the time
just before the occurrence of outcome event, while the control period
is defined as the time preceding the case period. The drug exposure
status during the case period is compared to that during the control
period. In a case–time–control study, non-cases are sampled as
controls to estimate the effect of exposure time-trend among the
cases. Case–case–time–control study is an extension of a case–time–
control study, where controls are sampled from future cases instead of
non-cases
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1.23–3.95) which was in line with the conclusion of the
SCCS analysis [IRR 3.38 (95 % CI 1.89–6.04)].
Risselada et al. [30] additionally applied CTC to address
the issue of exposure-time trend bias in CCO. This study
investigated whether the use of platelet aggregation inhi-
bitors (PAI) and vitamin K antagonist (VKA) were asso-
ciated with subarachnoid haemorrhage (SAH). Increased
prevalence of PAI and VKA use were observed over the
study period. For each case, the 1-month period preceding
the index date was compared to the prior 11 control peri-
ods, which also had a length of 1 month each. The CCO
analyses showed that SAH was positively associated with
VKA use (OR 2.90; 95 % CI 1.27–6.65). However, after
adjusting for the exposure-time trend in the CTC analyses,
the effect decreased to non-significant levels (OR 1.98;
95 % CI 0.82–4.76).
Other techniques
This article has so far focused on the pharmacoepidemio-
logical techniques in drug safety hypothesis testing using
automated databases. In recent years, there has been sig-
nificant methodological development in using spontaneous
reporting databases [31, 32] or prescribing data alone [33].
Methodologies such as disproportionality analysis [34] and
prescription sequence symmetry analysis are increasingly
popular [35]. However, due to the limitations of the quality
and quantity of available data, these techniques are used
mainly for drug safety hypothesis generation. Databases
are also commonly used to perform descriptive drug utili-
sation studies. Drug utilisation studies are particularly
useful in generating new information [36, 37] to decide
whether further analytical studies are required [38].
Meta-analysis of observational studies (secondary anal-
ysis of data from existing observational studies) has also
been increasingly applied for drug safety hypothesis testing
[39–41]. The basic principles are the same as traditional
meta-analysis of clinical trials, however, quality assess-
ment is more challenging and the methodology is still
evolving.
Finally, primary data collection in clinical settings is
rarely done in developed countries in recent years. It is
very labour-intensive and unlikely to be cost-effective in
pharmacoepidemiology research. However, in some cir-
cumstances, it is still the only appropriate method for
pharmacoepidemiology research such as monitoring drug
administration errors in nursing staff [42, 43]. Special
attention is needed to prevent interference in health pro-
fessionals’ clinical responsibilities and patient care.
Table 1 Summary of the strengths and limitations of various pharmacoepidemiological designs
Method Strengths Limitations
Cohort Exposure precedes outcomes
Can explore multiple outcomes
Allow rare exposures
Can estimate the incidence of outcomes
Time- and resource- consuming
Difficult to study rare outcomes
Case–control Can explore multiple exposures
Allow rare outcomes
Quicker and cheaper (compared to cohort studies)
Difficult to study rare exposures
Difficult to select proper cases and controls
Cannot estimate the incidence of outcomes
Self-controlled
case series
(SCCS)
Eliminates time-invariant confounders
Less data-intensive (compared to cohort or case–
control studies)
Temporal variables such as age can be accounted for
by subdividing the observation period
Sensitive to time-variant confounders
Cannot estimate the incidence of outcomes
Not suitable when any of the following assumptions is violated
Outcome events are rare or independent of each other
Occurrence of outcome event is independent of the exposures
Occurrence of outcome event or any subsequent conditions
stemming from the event should not censor the observation
period
Case-crossover
(CCO)
Eliminates time-invariant confounders
Less data-intensive (compared to cohort or case–
control studies)
Exposure-trend bias can be addressed by case–time–
control (CTC) or case–case–time–control (CCTC)
Sensitive to time-variant confounders
Cannot estimate the incidence of outcomes
Not suitable when any of the following assumptions is violated
Transient exposures and acute outcomes
Exposure has a stable trend over time
CTC and CCTC may reintroduce control-selection bias if the
external controls are not well-matched
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Furthermore, appropriate training for researchers is crucial
to ensure the validity and reliability of data collection.
Consequently, primary data collection in clinical settings
are being replaced gradually by automated databases in
pharmacoepidemiology research in developed countries.
Table 1 summarises the strengths and limitations of
various pharmacoepidemiological designs. Table 1 is
intended to assist readers with selecting the appropriate
design for future studies.
Conclusion
Observational studies are essential to inform the safe use of
medications. Classical epidemiological techniques such as
cohort and case–control design have been widely used to
investigate the association between drug exposure and
clinical outcomes. Derived from cohort or case–control
methods, case-only designs have been developed to elim-
inate time-invariable effect by self-matching. Such meth-
ods are gaining popularity among researchers in
epidemiological and drug safety research. Finally, large
databases provide useful platforms for observational stud-
ies to assess outcomes, including rare and long-term
adverse events of medications.
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